Journal
Synergy Rx Review 2026: '$199 Starting' Under a Promo Banner, Decoded
Released: Last reviewed:
Short answer — August 2026
Per July 2026 captures, Synergy Rx advertises injectable semaglutide "starting at one ninety-nine" and oral at two ninety-nine; injectable tirzepatide "starting at three forty-nine," oral three ninety-nine — beneath a site-wide "2026 Promo Applied" banner and a hundred-dollar welcome credit at checkout. That's two Teaser-Index mechanisms stacked (promo-anchoring on start-anchoring), which our tables record with labels rather than rank on. The counterweights: an all-fifty-state claim, and — unusually — advertised named pharmacies, which makes the verification runnable if the names survive intake. The numbers themselves, even taken at face value, sit high: one ninety-nine start-price semaglutide against one twenty-nine maintenance elsewhere; three forty-nine tirzepatide against the one sixty-nine-to-one seventy-nine tier.
The decode, and the questions
"Starting at" plus an active promo means your real price has two unknowns: what your dose costs after the entry tier, and what the rate becomes when the banner changes — so the enrollment questions write themselves: the ongoing maintenance-dose rate in writing; whether the promo/credit is a first-month event or a locked rate; the specific pharmacy filling my state's prescription (cash the named-pharmacies claim into names, then run the fifteen minutes). Note the format gradient repeats Direct Meds' inversion — the cheapest entries aren't the proven route, and the oral figures carry the sublingual-class caveat.
Verdict
Even granting every advertised figure, Synergy prices as an upper tier wearing promo dressing: the semaglutide start figure is seventy above the market's flat maintenance floor, and three forty-nine tirzepatide is a hundred dollars from an FDA-approved vial. The named-pharmacy posture is a genuine plus that better-priced anonymous programs lack — but transparency about the pharmacy doesn't offset opacity about the maintenance price, and until an enrollment confirmation states the latter, the row stays labeled. Fit: a buyer who values the named-pharmacy trail enough to extract the real rate in writing — and who compares that rate, not the banner, to the board.
Questions people ask
What does Synergy Rx cost?
Advertised (July 2026): injectable semaglutide 'starting at $199,' oral $299; injectable tirzepatide 'starting at $349,' oral $399 — under a '2026 Promo Applied' banner with a $100 welcome credit. Start-anchored plus promo-anchored means your maintenance-dose rate must come from enrollment, in writing.
Does Synergy Rx name its pharmacies?
Its marketing advertises named pharmacies — unusual and welcome. Cash the claim at intake: get the specific pharmacy for your state, then run the standard verification (license lookups, FDA compounding records, COA). The claim is only worth the names it produces.
Is Synergy Rx's $199 semaglutide competitive?
As a starting price, it's $70 above bmiMD's $129 maintenance-dose rate — before any post-entry escalation. Tirzepatide at $349 sits $170–$180 over the flat tier and $100 under an FDA-approved Zepbound vial. The advertised figures rank high even read charitably.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.